FINWIRES · TerminalLIVE
FINWIRES

Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment

By

(Updates with the latest stock move in the headline and in the first paragraph.)

UniQure (QURE) shares were up over 18% in Thursday trading after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.

The plan came after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, it said.

The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design.

The company said it is pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2.

Price: $19.82, Change: $+3.09, Percent Change: +18.47%

Related Articles

Wire

Cheesecake Factory Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Cheesecake Factory (CAKE) reported Q1 adjusted earnings late Wednesday of $1.05 per diluted share, up from $0.93 a year earlier.Analysts polled by FactSet expected $1.01.Revenue in the 13 weeks ended March 31 rose to $978.8 million from $927.2 million a year earlier.Analysts surveyed by FactSet expected $964.6 million.Cheesecake Factory shares rose 4.7% in after-hours trading.

$CAKE
Wire

Pilgrim's Pride Q1 Adjusted Earnings Fall, Sales Rise

Pilgrim's Pride (PPC) reported Q1 adjusted earnings late Wednesday of $0.51 per diluted share, down from $1.31 a year earlier.Analysts polled by FactSet expected $0.65.Net sales for the quarter ended March 29 rose to $4.53 billion from $4.46 billion a year earlier.Analysts surveyed by FactSet expected $4.43 billion.

$PPC
Wire

National Fuel Gas Fiscal Q2 Adjusted Earnings, Revenue Rise

National Fuel Gas (NFG) reported fiscal Q2 adjusted earnings late Wednesday of $2.71 per diluted share, up from $2.39 a year earlier.Analysts polled by FactSet expected $2.84.Revenue for the three months ended March 31 was $858.4 million, up from $730 million a year earlier.Analysts surveyed by FactSet expected $856.6 million.The company revised its fiscal 2026 adjusted EPS guidance range to $7.45 to $7.75 from $7.60 to $8.10 earlier. Analysts expect $7.79.

$NFG